AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05939791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
Study NCT05869279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARCIK-CD19
Description: allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
Study NCT05344690 — intervention group
Intervention type: GENETIC
Intervention: SLMAP and EPO genetic polymorphism
Description: Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Study NCT06140576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindilimab
Description: Sindilimab, 200mg, Intravenous，every three weeks
Study NCT06140576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
Study NCT06140576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8mg, 12mg, 16mg everyday
Study NCT05197153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Half dose of MVC-COV1901
Description: Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
Study NCT05197153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose of MVC-COV1901
Description: Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
Study NCT05197153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
Study NCT05197153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Half dose of mRNA-1273
Description: Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
Study NCT05465486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface control of robotic arms with augmented reality
Description: The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab.
Study NCT05465486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface control of robotic arms with augmented reality
Description: The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab.
Study NCT05465486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serious game with augmented reality
Description: The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab
Study NCT05465486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Serious game with augmented reality
Description: The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab
Study NCT06538519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement using lateral approach
Description: In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.
Study NCT06538519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement using anterior approach
Description: the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.
Study NCT06538519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gait analysis at 6wks, 3 months and 18 months
Description: gait analysis done in the gait lab at the mentioned postoperative periods
Study NCT05454254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualised muscle strengthening exercise training protocol.
Description: Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
Study NCT05896696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeShape One
Description: Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
Study NCT06008106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tunlametinib
Description: 12mg BID
Study NCT06008106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
Description: according to investigators' suggestion
Study NCT06442293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: A dietary supplement containing beet root extract, arginine and citrulline
Study NCT06442293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
Study NCT06442293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo supplement that is similar in appearance to treatment 1
Study NCT05540418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lavender oil inhalation
Description: Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
Study NCT06399341 — intervention group
Intervention type: DEVICE
Intervention: Papilocare vaginal gel
Description: Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)
Study NCT06096818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: Kegel exercises and abdominal exercises
Description: The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled.
Study NCT06096818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group: Kegel exercises
Description: The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled.
Study NCT06475027 — intervention group
Intervention type: OTHER
Intervention: TBDESJS
Description: Chinese herbal tea TBDESJS
Study NCT06475027 — intervention group
Intervention type: OTHER
Intervention: Acupuncture
Description: acupuncture GB20 or GB20 plus BL2
Study NCT06304558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Neuromodulation (NESA)
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
Study NCT06304558 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Invasive Neuromodulation (NESA)
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
Study NCT05347134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKB264
Description: SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT04722952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) > 5X109／L or white blood cell（WBC）> 20X109／L.
Study NCT05191667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: 250 mg or 500 mg Q.D., oral administration
Study NCT05111392 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of one (1) liter of beverage with observation for 2 h
Study NCT05111392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution 1
Description: Ingestion of one (1) liter of beverage with observation for 2 h
Study NCT05111392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution 2
Description: Ingestion of one (1) liter of beverage with observation for 2 h
Study NCT06400407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst Stimulation
Description: Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The total course of treatment lasted 7 days.
Study NCT06400407 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The total course of treatment lasted 7 days.
Study NCT05482165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-faceted health promotion programme
Description: This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses
Study NCT05921149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (Xentigen by L'Nutra)
Description: L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
Study NCT05921149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05921149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05921149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05921149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT05921149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet
Description: Normal diet
Study NCT05101083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Receiver-in-Canal Device
Description: Successor of previous device generation
Study NCT05101083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Legacy Receiver-in-Canal Device
Description: Receiver-in-canal device available on the market
Study NCT05463926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDA mobile application
Description: Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Obinutuzumab
Description: Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Bendamustine
Description: Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05899621 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT05098756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
Study NCT05362760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Aromatase Inhibitor
Description: Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
Study NCT05362760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Fulvestrant
Description: Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
Study NCT06041178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% flurbiprofen
Description: Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
Study NCT06041178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 98% aloe vera
Description: the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
Study NCT06041178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline